The present study was designed to examine differences in the effect of the number of children in the household (also known as “parity”) on the relationship between initiating joint attention (IJA) and language development. We reasoned that infants who are only children (i.e., in uniparous homes), relative to infants who have one or more siblings (i.e., in multiparous homes), would have more opportunity to engage in IJA, and would, therefore, acquire a larger number of object labels. We tested the hypotheses that: 1) there would be a positive correlation between the number of IJA bids and language overall, and 2) parity would moderate the IJA-language relationship such that in uniparous households, the aforementioned correlation would be stronger than in multiparous homes. Joint attention was measured using the Early Social Communication Scales (ESCS) Picture Book Task, and language was assessed through parental report on the MacArthur-Bates Communicative Development Inventory (MBCDI). There was no significant correlation between IJA and language on the whole, though there was a significant correlation for infants in uniparous homes between IJA and language. This finding partially supports Hypothesis 2 in terms of the IJA-language relationship being stronger in uniparous homes rather than multiparous ones, though it was only true for productive vocabulary. These null findings may provide reassurance for families with multiple children that their younger children are not at an IJA/language acquisition disadvantage.

Introduction: In acute myeloid leukemia (AML), leukemia initiating cells exist within the CD34+/CD38- cell compartment. They are assumed to be more resistant to chemotherapy, enriched in minimal residual disease cell populations, and responsible for relapse. Purpose: We evaluated clinical and biological associations and the prognostic impact of a high diagnostic CD34+/CD38- cell burden in AML patients receiving an allogeneic stem cell transplantation (HSCT) in complete remission. Here, the therapeutic approach is mainly based on immunological graft-versus-leukemia effects. Methods: Percentage of bone marrow CD34+/CD38- cell burden in 169 AML patients at diagnosis was measured using flow cytometry. The optimal cutoff of 6% was applied and used to evaluate the impact of a high CD34+/CD38- cell burden on outcome. Results: The CD34+/CD38- cell burden and was highly variable (median 0.5%, range 0-89% of all mononuclear cells). A high CD34+/CD38- cell burden at diagnosis associated with worse genetic risk and secondary AML. Patients with a high CD34+/CD38- cell burden had shorter relapse-free and overall survival, which may be mediated by residual leukemia initiating cells in the CD34+/CD38- cell population, escaping the graft-versus-leukemia effect after allogeneic HSCT. Conclusion: Evaluating the CD34+/CD38- cell burden at diagnosis may help to identify patients at high risk of relapse after allogeneic HSCT. Further studies to understand leukemia initiating cell biology and develop targeting therapies to improve outcomes of AML patients are needed.:Bibliographische Beschreibung / Bibliographic description 1 Einleitung / Introduction 2 Epidemiology and AML diagnosis 2 Therapeutic options in AML 3 Genetic risk classification for therapeutic decisions in AML 6 Immunophenotyping in AML 10 Leukemia Initiating Cells 11 Objectives of the here presented study 13 Publikation / Publication 14 Anlage / Supplemental Material 23 Zusammenfassung / Summary 48 Weiterführende Arbeiten / Future developments GPR56 as new LIC marker 52 Referenzen / References 55 Referenz der Publikation / Reference of the publication 60 Erklärung über die eigenständige Abfassung der Arbeit 61 Curriculum Vitae 62 Komplette Publikationsliste 65 Danksagung 74

CD133, a pentaspan glycoprotein, has long been known to represent aggressive, stem-like populations across various human malignancies. While its expression correlates with numerous clinical outcomes including disease progression, metastasis, recurrence, and poor overall survival in numerous cancers, little is currently known about its function. In the brain cancer glioblastoma (GBM), CD133-expressing cells have previously been shown to initiate tumours, evade therapy and interestingly, self-renew, a key property of cancer stem cells. With an implied signalling role in driving self-renewal, we aim to elucidate the role of CD133 in glioblastoma. To understand the role of CD133, we aim to study its protein-protein interactions using the proximity-dependent labelling technique known as miniTurboID. By tagging proteins of interest with a promiscuous biotin ligase at both protein termini, potential interactors can be biotinylated and identified by subsequent mass spectrometry. While miniTurboID has traditionally been performed by synthetic transgenes expressing the tagged proteins of interest in commercial cell lines, overexpression may not recapitulate its native function. Thus, using CRISPR technology, we aim to insert the miniTurboID ligase at both the N- and C-terminus of CD133 in patient-derived human GBM lines. Although little is currently known about CD133 function, development of targeted therapies has presented a promising strategy in pre-clinical studies. In the Singh Lab, we previously developed a chimeric antigen receptor T-cell, or CAR-T, comprised of a T-cell expressing a synthetic receptor capable of recognizing a tumor-associated antigen and activating cytolytic-killing directed towards the target cell. Currently, CAR-T therapies are autologous, or patient-derived, in nature which may host a myriad of concerns including patient-specific qualitative and quantitative T-cell dysfunction, inconsistent generation of CAR products, and availability to rapidly progressing patients. To circumvent this concern, “off-the-shelf”, donor-derived or allogeneic CAR-T products may be generated for use in GBM patients. However, in addition to CAR integration, allogeneic products must be additionally modified to eradicate expression of the endogenous TCR, as this would induce a phenomenon known as graft versus host disease, in which healthy tissues are targeted. Thus, in this thesis, we show gene editing potential in human GBMs to perform an endogenous genomic knock-in of miniTurboID. With the identification of interacting proteins, defining the subsequent functionality of CD133 may elucidate oncogenic cellular programs, and highlight common nodes of interaction within divergent cell signaling pathways. To develop an allogeneic CAR-T product, we designed a two-step approach in which the CAR sequence was integrated into the TCR gene for simultaneous knock-out. We later show early pre-clinical efficacy in comparison to traditional autologous CAR-T in our patient-derived models of human GBM. Thus, by using CD133 as a centralizing concept in this thesis, we ultimately hope to develop our biological understanding of CD133, while testing the therapeutic development of a donor-derived CAR-T therapy. / Thesis / Master of Science (MSc) / Glioblastoma (GBM) is one of the most common malignant brain tumors in adults. Despite an aggressive therapy regimen, almost all patients relapse 7-9 months post-diagnosis. Therapy failure and poor patient outcome may be attributed to a small population of cells known as glioblastoma stem cells, or GSCs, that are able to escape therapy and seed disease recurrence. GSCs are most notably identified by the cell surface protein CD133, which has previously been shown to associate with pro-tumor properties including treatment resistance, tumor growth, maintenance, progression and metastasis. While expression of CD133 in cancer has been heavily characterized, little is currently known about its function. One such avenue to understand its mechanism of action in cancer, and more particularly GBM, is to define its interactions with other proteins. Protein-protein interactions play a pivotal part as the backbone of signalling pathways that drive tumor development and growth. Therefore, defining and mapping the CD133 interaction network may help us understand how this protein governs regulation of GSCs, and ultimately, GBM progression. While the biology of CD133 has yet to be elucidated, targeting CD133 on GSCs has presented a promising therapeutic strategy for patients with GBM. Previously in the Singh Lab, we developed an engineered T-cell therapy, known as a CAR-T, that can recognize CD133 to induce tumor cell death. While this showed success in our animal models of human GBM, other considerations must be addressed on its path to clinical development. As of current, CAR-T therapies are generated from T-cells taken from cancer patients. This hosts a myriad of concerns including the quality of patient T-cells, the time and cost to manufacture, and its availability for patients with rapidly progressing disease. To circumvent this issue, donor-derived CAR-T cells can be genetically engineered for safe usage in GBM patients as a readily available, “off-the-shelf” therapy. To define the function of CD133, we have attempted to use a technique known as BioID, which tags the protein of interest with a smaller biotin ligase. This biotin ligase can subsequently tag proteins that come within the vicinity of CD133, that may later be identified by sequencing as potential interactors. As current use of BioID may not reliably mimic the interaction of CD133, we sought to genetically engineer human GBM lines with the BioID protein to more closely resemble tumor-relevant behaviours of CD133. To develop a donor-derived CAR-T therapy, we similarly used genetic engineering of T-cells to ensure specific targeting of tumor cells with CD133, while sparing healthy tissues. By using CD133 as a centralizing concept in this thesis, we ultimately hope to develop our biological understanding of CD133, while testing the therapeutic development of a donor-derived CAR-T therapy.

No description available.

Prostate cancer (CaP) is the second leading cause of cancer related deaths in men in the United States. Currently, androgen depletion is an essential strategy for CaP combined with surgery, chemotherapy and radiation. Hormone independent cancer stem cells escaping conventional therapy present a major therapeutic challenge. The available treatment regimens for hormone resistant CaP are only palliative and marginally increase survival. Therefore, novel strategies to eradicate CaP including stem cells are imperative. Oncolytic virus (OV) therapy is a novel approach that overcomes the limitations posed by radiation and chemotherapy. Oncolytic virotherapy of cancer is based on the use of replication competent, tumor selective viruses with limited toxicity. Newcastle Disease Virus (NDV), an avian paramyxovirus, is a safe and promising OV successfully used in many clinical trials. NDV is inherently tumor selective and cytotoxic but replication restricted in normal cells. But, systemically delivered NDV fails to reach solid tumors in therapeutic concentrations and also spreads poorly within the tumors due to barriers including complement, innate immunity and extracellular matrix. Overcoming these hurdles is paramount to realize the exceptional oncolytic efficacy of NDV. Therefore, we engineered the fusion (F) glycoprotein of NDV and generated a recombinant NDV (rNDV) cleavable exclusively by prostate specific antigen (PSA). The rNDV replicated efficiently and specifically only in prostate cancer (CaP) cells but failed to replicate in the absence of PSA. Further, PSA-cleavable rNDV caused specific lysis of androgen independent and dependent/responsive CaP cells with a mean effective concentration (EC50) ranging from 0.01 to 0.1 multiplicity of infection (MOI). PSA retargeted rNDV efficiently lysed three-dimensional prostaspheres, suggesting efficacy in vivo. Also, PSA-cleavable NDV failed to replicate in chicken embryos, indicating absence of pathogenicity to its natural host, chickens. Prostaspheres generated from DU-145 CaP cell line derived xenografts showed self-renewal, proliferative and clonogenic potential in vitro, and exhibited increased tumorigenicity in vivo. Embryonic stem and progenitor cell markers like Nanog, Nestin and CD44 were overexpressed in spheres as compared to the cell line suggesting prostaspheres comprise tumor-initiating cells from CaP. Xenograft and cell line derived prostaspheres were permissive for rNDV replication, when the fusion protein was activated by exogenous PSA. The EC50 against tumor initiating cells was 0.11-0.14 MOI, suggesting an excellent therapeutic margin for in vivo studies. PSA retargeting is likely to enhance the therapeutic index of rNDV owing to tumor restricted replication and enhanced fusogenicity. Our results suggest PSA retargeted rNDV selectively replicates and lyse PSA producing CaP cells including tumor-initiating cells and is a promising candidate for immediate Phase I/II clinical trials. / Ph. D.

La littérature récente suggère que certaines sous populations cellulaires appelées cellules initiatrices de tumeurs (CIT) seraient particulièrement résistantes aux traitements actuels qui visent préférentiellement les cellules prolifératives et, de ce fait, participeraient activement à l'initiation de récidives tumorales et à la formation des métastases. La caractérisation de ces cellules ainsi que de leurs régulateurs revêt par conséquent un intérêt considérable pour la recherche fondamentale et translationnelle. La progastrine est une pro-hormone sécrétée en quantité anormalement importante par la majorité des tumeurs colorectales et qui joue un rôle important dans la promotion du développement tumoral. Les données publiées du laboratoire montrent en effet que l'inhibition de la PG conduit à la baisse des activités WNT/b-caténine et Notch qui sont des voies de signalisations anormalement activées dans les cancers colorectaux (CCR) et nécessaires au maintien des CIT coliques. Ainsi, le but de ce travail de thèse a été de déterminer si la PG possède un rôle régulateur des CIT coliques. Nos résultats indiquent que la PG est fortement exprimée dans des modèles cellulaires enrichis en CIT tels que le sont les colosphères ou les cellules exprimant fortement l'activité enzymatique des aldéhydes déshydrogénases (ALDH+). Le ciblage de la PG, soit par ARN interférent soit par l'utilisation d'anticorps neutralisant la PG dans des lignées cellulaires ou dans des cellules fraichement isolées de biopsies d'adénocarcinomes coliques humains, altère fortement la capacité d'initiation de colosphères sur plusieurs générations alors que le phénotype est sauvé par l'ajout de PG exogène. Ces résultats reflètent un potentiel d'autorenouvellement moindre des CIT in vitro en absence de PG. Le nombre de cellules ALDH+ diminue aussi significativement en absence de PG. À l'inverse, l'ajout de PG exogène stimule da capacité d'initiation des colosphères et augmente le nombre de cellules ALDH+. In vivo, la diminution de l'expression de la PG dans les cellules ALDH+ permet un délai dans l'initiation tumorale et diminue de 16x la propagation des CIT lors du deuxième passage chez la souris immunodéprimée. Ainsi, la PG est sécrétée par les CIT coliques, et, en retour, cette pro-hormone régule le maintien de ces cellules. Enfin, même si le rôle de la PG dans le tissu intestinal sain n'est pas primordial, nos résultats montrent qu'elle est produite par des cellules situées au fond des cryptes intestinales. Nos résultats viennent conforter l'idée selon laquelle le ciblage de la PG représente une stratégie thérapeutique prometteuse pour le traitement du CCR. / Recent literature strongly suggests that tumor initiating cells (TIC), resistant to chemotherapies, would be responsible for recurrence and metastasis development in colorectal cancer. Discovering new targets to eradicate these cells become urgent. Our team has shown that Progastrin (PG), a hormonal precursor abnormally secreted by most of colorectal tumors, would be a promising therapeutic target for colorectal cancer (CRC). In a mouse model developing spontaneously intestinal tumors, PG expression reduction leads to tumor growth decrease and remaining tumors display an increase of cell differentiation. Interestingly, tumorigenesis diminution is mediated by WNT-bcatenin and Notch transcriptional activity inhibition. These pathways being abnormally activated in CRC and essential for TIC survival and self-renewal, the aim of this work is thought to characterize PG involvement in TIC phenotype. Our results indicate that Progastrin is produced in TIC enriched models such as in colonospheres and in cells that highly expressed Aldehyde Dehydrogenase (ALDH+) activities. Targeting PG by RNAi or using neutralizing antibodies in cell lines or in cells that were freshly isolated from human's colon adenocarcinoma leads to decrease colonosphere number and self-renewal. Moreover, ALDH+ cells number decline after PG downregulation. In contrast, PG supplementation increases colonospheres initiation as well as ALDH+ cell number. In vivo, PG downregulation in ALDH+ cells that usually secretes PG leads to tumor initiation delay even after a second passage of bulk cells in immunodeficient mice. These results suggest also TIC frequency decrease in absence of PG. Thus, we show that PG is secreted by TIC and regulates their activities. Finally, PG role is not primordial for intestinal tissue homeostasis but our results show that this pro-hormonal precursor is preferentially produced at the bottom of intestine crypt cells. To conclude, our results strongly consolidate the idea of targeting Progastrin as a promising therapeutic strategy for colorectal cancer management.

Abstract This cross-sectional survey study investigated middle and high school administrative team members’ leadership classifications and perceptions of secondary principals’ leadership actions and behaviors in the context of change and to what extent these perceptions are gender specific. In addition to gender, the study also examined the impact of race/ethnicity, age, campus level, length of employment in the district, length of time working with the principal, and closeness to the principals on leadership actions and behaviors. The results of the study are intended to highlight the importance and value of feminine-inspired leadership approaches and administrative team members’ perspectives of leadership in managing and leading the change process. The study targeted the leadership actions and behaviors of 39 middle school and 28 high school principals assigned to traditional secondary schools in the southwestern United States. Administrative team members’ perceptions of secondary school principals’ approaches to leadership served as the basis for the study, which investigated whether administrative team members perceived principals’ leadership actions or behaviors in a change context to be gender specific. Male and female administrative team members (n=210) were surveyed using the Leader Behavior Description Questionnaire (LBDQ), Form XII – fourth revision (Ohio State University, 1962). Based on survey results, secondary principals were classified as dynamic, considerate, passive, and structured leaders as rated by administrative team members using the LBDQ. The results of the study revealed that gender and school level of administrative team members did not influence the classification of secondary principals as dynamic, considerate, passive, or structured leaders. The ratings of those principals perceived as dynamic were statistically significantly higher than those of principals as passive and structured leaders. Out of 62 secondary principals, administrative team members classified principals as follows: dynamic leaders 63% (n=39), considerate leaders 5% (n=3), passive leaders 16% (n=10) and structured leaders 16% (n=10). Additionally, dynamic leaders received a statistically significant higher rating of closeness to principal when compared to passive and structured leaders. The findings of the study, which illuminate the perspectives of administrative team members with regard to secondary school principals, have implications for informing research on school leadership as well as educational leadership practices.

As neoplasias mamárias apresentam um grande desafio tanto para a medicina humana, quanto para a medicina veterinária. Esses tumores apresentam ampla heterogeneidade intertumoral e intratumoral, dificultando assim a busca por tratamentos eficazes. Recentemente, pesquisadores tem voltado sua atenção para uma população de células que apresentam características muito semelhantes as células-tronco. São as chamadas células iniciadoras de tumores (CITs). Estas são descritas como as principais responsáveis por falhas nas quimioterapias e no surgimento de recidivas tumorais, devido ao seu potencial tumorigênico, de auto-renovação e de resistência a drogas antineoplásicas. Entretanto, o estudo dessas células é limitado pelas dificuldades no isolamento e na caracterização pós-enriquecimento dessas células, devido à perda do fenótipo em modelos in vitro. Sendo assim, vários estudos estão buscando maneiras alternativas de enriquecer essa população. Uma das maneiras mais utilizadas, baseia-se na indução do processo de transição epitélio-mesenquimal, através da superexpressão de fatores de transcrição como SNAI1, SLUG, ZEB1 e ZEB2. Sendo assim, nós objetivamos expressar de maneira exógena os fatores de transcrição SLUG e ZEB1 em células oriundas de carcinomas mamários caninos, caracterizar seus efeitos nessas células e observar se esses fatores de transcrição seriam capazes de induzir o fenótipo de CIT. Primeiramente, quatro amostras de carcinomas mamários caninos foram analisados quanto sua morfologia e os níveis de expressão gênica de quatro fatores de transcrição associados a transição epitélio-mesenquimal: SLUG, STAT3, ZEB1 e ZEB2. Após, nós selecionamos duas dessas amostras (CC-20E e CL-28E), que apresentavam morfologia típica de células epiteliais e baixa expressão dos fatores de transcrição citados acima e expressamos de maneira exógena e de forma estável os fatores de transcrição SLUG e ZEB1, através do processo de transdução lentiviral. Entretanto, apenas a transdução com os plasmídeos contendo a região codificante de SLUG foi eficiente. Sendo assim, nós avaliamos os efeitos da expressão exógena de SLUG nas células CC-20E e CL-28E, quanto a alteração de morfologia e expressão de filamentos intermediários como citoqueratina, vimentina e actina. Além disso, nós avaliamos se a expressão exógena de SLUG poderia regular a expressão de outros genes associados a EMT, além de genes supressores de tumores, alvos de SLUG. Por fim, nós avaliamos se a expressão exógena de SLUG poderia induzir ao fenótipo de CITs, verificando se havia alteração na sensibilidade das células aos quimioterápicos doxorrubicina e paclitaxel, além de avaliar o potencial tumorigênico e de auto-renovação dessas células em cultivos de baixa aderência. A expressão exógena de SLUG nas células CC-20E e CL-28E, não induziu a alterações na morfologia epitelial das células. Entretanto, as células alteraram sua disposição em monocamada no cultivo, formando tipos de túbulos semidiferenciados, característicos do processo de EMT híbrido ou parcial. Além, disso, houve um equilíbrio entre a expressão dos filamentos intermediários de citoqueratina e vimentina nas células, além do aumento na expressão dos genes CDH1 (E-caderina) e CDH2 (N-caderina), resultado que sustentou a indução de EMT parcial. O processo de EMT parcial induziu maior resistência ao quimioterápico paclitaxel, além de potencializar a tumorigenecidade e a capacidade de auto-renovação das células em cultivos de baixa aderência. Sendo assim, no presente estudo, nós obtivemos um cultivo com características que mimetizam as CITs, demonstrando que os processos que induzem esse fenótipo são semelhantes tanto na espécie canina, quanto em humanos, sustentando a hipótese de que neoplasias mamárias caninas podem servir como modelo para o estudo das CITs e, consequentemente, do desenvolvimento neoplásico de tumores sólidos. / Mammary neoplasms present a major challenge for both human and veterinary medicine, due to intertumoral and intratumoral heterogeneity, hindering the search for effective treatments. Recently, researchers has highlighted a population of cells with features very similar to stem cells. Known as Tumor-Initiating Cells (TICs), they are described as the main responsible for chemotherapy failures and tumor recurrence, due to their tumorigenic potential, self-renewal ability and drug resistance. The study of TICs is limited mainly by their difficult isolation owing to specific markers absence, and furthermore, cells lose their phenotype when placed in vitro. Therefore, several studies are seeking for alternatives to enrich this population in regular cultures. One way is based on the epithelial-mesenchymal transition induction through of transcription factors overexpression, such as SNAI1, SLUG, ZEB1 e ZEB2. So, the aim of this study was to overexpresse the SLUG and ZEB1 transcription factors in a cell culture derived from canine mammary carcinomas, evaluate its effects and observe whether these transcription factors would be capable of inducing the TIC phenotype. First, four canine mammary carcinomas cell cultures were analyzed for their morphology and gene expression levels of four transcription factors associated with epithelial-mesenchymal transition: SLUG, STAT3, and ZEB1 ZEB2. After, we selected two samples (CC-20E and CL-28E) with typical morphology of epithelial cells and low expression of the transcription factors mentioned above. We then overexpress, stably, the transcription factors SLUG and ZEB1 by lentiviral transduction, However, only SLUG transduction was efficient. Then, we evaluated the effects of SLUG overexpression in CC-20E and CL-28E cells as the change of morphology, expression of intermediate filaments as cytokeratin, vimentin and actin. In addition, we evaluated whether SLUG overexpression could regulate the expression of other EMT-associated genes as well as tumor suppressor genes, and assessed evaluated the tumorigenic potential and self-renewal of these cells in low adherence cultures. Finally, we assessed whether SLUG overexpression could induce drug resistance through doxorubicin and paclitaxel sensivity assay. The SLUG overexpression did not induce modification in epithelial cell morphology, however, cells changed their arrangement in monolayer culture, inducing the semidifferentiated tubules, typical of hybrid or partial EMT process. In, addition, there was a balanced expression between cytokeratin and vimentin, possibly explained by an increase in CDH1 expression (E-cadherin) and CDH2 (N-cadherin) typical of partial EMT. Furthermore, the partial EMT generated cells presenting paclitaxel resistance, and enhanced the tumorigenic potential and self-renewal capacity of the cells on low adherent plates. Thus, in this study, we obtained a cell culture exhibiting features that mimics the TICs, demonstrating the mechanisms which regulate this phenotype are similar in dogs and humans, supporting the hypothesis that canine mammary carcinomas are a great model for the study of TICs and solid tumors development.

Au cours de ma thèse, je me suis intéressée à une population cellulaire rare et peu étudiée de l’épithélium intestinal ; les cellules tuft. La fonction de ces cellules fut longtemps débattue dans la littérature, jusqu’à ce que nous découvrions leur fonction dans l’initiation de la réponse immune de type II en réponse à une infection parasitaire. De manière intéressante, ces cellules sont présentes de manière massive et transitoire au sein des lésions adénomateuses précoces et certains groupes ont suggéré l’implication de ces cellules en tant que cellules souches tumorales. Les principaux objectifs de ma thèse ont été de déterminer le rôle des cellules tuft au cours de la tumorigenèse intestinale et colorectale.Nous avons montré que l’absence de cellules tuft impacte le processus de tumorigenèse à la fois dans l’intestin grêle, dans des souris de la lignée Apc14/+, et au niveau du colon, après traitement avec un agent carcinogène. Nos données indiquent que si les cellules tuft n’agissent pas en tant que cellules souches tumorales, leur absence impacte certaines populations de cellules immunitaires. Afin de déterminer les mécanismes permettant aux cellules tuft de moduler le microenvironnement immunitaire, nous avons identifié par analyse transcriptomique de cellules tuft isolées par cytométrie en flux, des gènes codant pour des médiateurs connus pour être impliqués dans la communication avec le système immunitaire. Des analyses in-vivo, permettront de valider d’un point de vue fonctionnel l’implication de ces médiateurs immunitaires dans la fonction immuno-régulatrice des cellules tuft ainsi que dans le développement tumoral.L’ensemble de ces travaux a permis d’identifier une fonction immuno-régulatrice des cellules tuft au cours d’une infection parasitaire, mais aussi très probablement lors du développement tumoral. La compréhension des mécanismes permettant aux cellules tuft de moduler certaines populations de cellules immunitaires permettra d’identifier des cibles d’intérêt thérapeutique potentiel pour le traitement de patients atteints d’un cancer colorectal. / I focused my PhD project on a scare epithelial cell population referred as tuft cells. Their function has been debated for decades in the literature, until we discovered their crucial role in the initiation of the so-called type-2 immune response following parasitic infection. Interestingly, tuft cells are present in early adenomatous intestinal lesions and literature suggested that these cells could act as cancer stem cells. The main objective of my PhD was to determine the tuft cell function during intestinal and colorectal cancer.We showed that tuft cells deficiency impacts both intestinal and colorectal tumorigenesis process, using Apc14/+ mouse strain and chemically induced carcinogenesis model, respectively. Our data indicate that tuft cells are not cancer stem cells, but that these cells are able to regulate immune cell populations. To get more insights into mechanisms allowing tuft cells to modulate the immune microenvironment, we identified, by transcriptomic analysis of FACS-isolated tuft cells, specific genes encoding mediators involved in the crosstalk with the immune system. Functional in-vivo validation of the most relevant candidates will identify tuft cells derived factors crucial for the immune-regulatory tuft cell function and for tumor development.This work allowed to highlight the immune-regulatory function of tuft cells during parasitic infection and likely during tumor development. A better knowledge of the mechanisms allowing tuft cells to shape either a pro- or an anti-tumoral microenvironment, will potentially paves the way for new therapeutic strategies regarding intestinal and colorectal tumorigenesis.

Le Cancer Colo Rectal (CCR) est la deuxième cause de mortalité par cancer dans le monde. Le risque de récidive après traitement curatif atteint 45% pour les stades 3. Une des hypothèses à l’heure actuelle pouvant expliciter le processus métastatique et les récidives est la présence en son sein de cellules « souches », pouvant « initier » le cancer. Notre réflexion s’inscrit dans la continuité des travaux réalisés au sein de notre Laboratoire, intitulés «Stratégies d’isolement et de caractérisation des cellules initiatrices de cancer colorectal», (Mélin et al, 2012). Dans une première partie, notre travail a porté sur l’analyse in vitro de la sensibilité des fractions enrichies en CIC aux différentes molécules de chimiothérapie les plus couramment utilisées en cancérologie colorectale.Puis, dans une deuxième partie, l’analyse des tumeurs obtenues après greffe a été faite ex ovo sur la Membrane Chorio-Allantoïdienne d’embryon de poulet (CAM), modèle facilement manipulable, peu onéreux et très rapide. Ce modèle étant naturellement immunodéprimé, il permet d’obtenir des informations concernant les phénomènes clés de la tumorigénèse et de la néoangiogénèse. Des analyses de la croissance tumorale, de l’histologie (prolifération, apoptose et vascularisation) et des analyses protéiques ont été menées en parallèle. De cette dernière étude, un marqueur particulier la E cadhérine, a été mis en évidence comme témoin indirect d’agressivité. En effet, au sein des tumeurs obtenues à partir de F1 HCT116, fraction himiosensible, l’expression de la E cadhérine est augmentée contrairement aux tumeurs obtenues à partir de F3 WiDr, fraction chimiorésistante, montrant une diminution d’expression de la E cadhérine.Ainsi, dans une troisième partie, sachant qu’un lien entre cellules initiant le cancer et E cadhérine a été mis en évidence, nous nous sommes focalisés sur son expression. Nous avons alors étudié son expression in vitro sur des cellules résistantes au 5 Fluorouracile. Puis, son expression a été étudiée ex vivo au sein de tissus et de sérums de patients opérés de cancer colorectal. / The ColoRectal Cancer (CCR) is the second leading cause of cancer mortality in the world. The risk of recurrence after curative treatment reaches 45% for stages 3. One of the hypotheses currently able to explain the metastatic process and the recurrences is the presence within it of "stem" cells, which can "initiate" the cancer. Our reflection is in line with the work carried out in our Laboratory, entitled "Strategies for the isolation and characterization of cells that initiate colorectal cancer" (Mélin et al, 2012).In the first part, our work focused on in vitro analysis of the sensitivity of fractions enriched in CIC to different chemotherapy molecules most commonly used in colorectal cancer (CRC). Then, in a second part, the analysis of the tumors obtained after transplantation was made ex ovo on Chicken Embryo Chorio-Allantoid Membrane (CAM), an easily manipulated model, inexpensive and very fast. This model provides information on the key phenomena of tumorigenesis and neoangiogenesis. Analyzes of tumor growth, histology (proliferation, apoptosis and vascularization) and protein analyzes were carried out in parallel. From this last study, a particular marker, E cadherin, was highlighted as an indirect link with witness of aggressiveness. Indeed, within the tumors obtained from F1 HCT116, the chemosensitive fraction, the expression of cadherin E was increased in contrast to the tumors obtained from F3 WiDr, chemoresistant fraction, showing a decrease in expression of E cadherin.Thus, in a third part, knowing that a link between cells initiating cancer and E cadherin was highlighted, we focused on its expression. We first studied its expression in vitro on 5 Fluorouracilresistant cells. Its expression was then studied ex vivo in tissues and sera of operated patients of CRC.